Merck announced on January 14, 2025, plans to speed up the launch of a new subcutaneous version of its blockbuster cancer drug, Keytruda. This strategic move comes as the patent expiration for the intravenous formulation approaches.
The development of a more convenient, injectable version of Keytruda is crucial for Merck to maintain market share and extend the product's lifecycle. This aims to mitigate the impact of biosimilar competition once the main U.S. patent expires in 2028.
Accelerating the launch demonstrates Merck's proactive approach to managing its portfolio and ensuring continued access to its leading oncology therapy. This initiative is a key component of the company's long-term growth strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.